321 / 1498
CMT / Chemo for early stage
• No RCT
• RT outcome is excellent. Difficult to improve on
.
• Limited data on role of
CMT
in early stage dis
–
Canadian
data on short course ABVD suggests benefit
– but other studies (
MDACC, GHSG, Harvard
) show
no
benefit
– RT alone remains standard
• Chemo alone
strategy in
children
: limited data
• Rituximab alone
: limited data
(GHSG 28 pts, Stanford 13 pts):
– 100% response, but 25% relapse. Not recommended.